arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

IceCure Medical Ltd.

ICCM

$3.03 ▼ -0.05 (-1.46%) at close

7 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Moderately Bearish

auto_awesome

Analytical Summary

IceCure Medical Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $192.6M

Dividend Yield —

Revenue Growth 2.7% ↗

Op. Margin -446.7% ↗

ROIC -131.6% ↗

FCF / Share $-0.23 ↗

Trailing P/E 12.6x

Price / Book 24.5x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.38M

↑ +2.7% —

Net Income Profit after all expenses

$-15.06M

↑ +1.7% —

Operating Margin Operating profit as % of sales

-446.7%

↑ +6.3% 0th

FCF / Share Free cash flow per share

$-0.23

↑ +7.5% —

Long-Term Debt Long-term obligations

$13.00K

↓ -91.9% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 7 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Revenue Growth YoY (%)	2.7% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-67%)	1.9% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-76%)	4.7% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-42%)	-25.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-418%)	7.0% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-13%)	—	—
EPS Growth YoY (%)	-20.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-6.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-30.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	31.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	59.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	1.7% Caution ↑ Caution Improving Year-over-year change in net income	-4.5% Weak ↑ Weak Improving Year-over-year change in net income	13.7% Fair ↑ Fair Improving Year-over-year change in net income	-71.6% Weak Weak Year-over-year change in net income	-165.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	7.5% Fair ↓ Fair Declining Year-over-year change in free cash flow	13.0% Fair ↑ Fair Improving Year-over-year change in free cash flow	30.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	10.9% Fair Fair Year-over-year change in free cash flow	-101.4% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	3.1% Caution ↑ Caution Improving Compound annual revenue growth over 3 years	-7.3% Weak Weak Compound annual revenue growth over 3 years	-5.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-2.7% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—
EPS CAGR 3Y (%)	-19.5% Weak ↓ Weak Declining Compound annual EPS growth over 3 years	-5.0% Weak Weak Compound annual EPS growth over 3 years	13.3% Good Good Compound annual EPS growth over 3 years	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Operating Margin (%) (%)	-446.7% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3078%)	-476.9% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3280%)	-482.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3316%)	—	-235.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1667%)	—	—
Profit Margin (%) (%)	-445.6% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3813%)	-465.5% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3979%)	-453.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3881%)	—	-239.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2093%)	-96.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-904%)	—
FCF Margin (%) (%)	-432.4% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-383.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-403.5% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-492.2% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-317.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-101.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.33x Good Good Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Return on Invested Capital (%)	-131.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-175.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-101.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-52.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	57.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-108.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-124.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-94.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-55.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	40.5% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-166.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1209%)	-222.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1580%)	-120.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-903%)	-66.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-545%)	-36.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-345%)	-66.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-540%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Debt to Equity (x)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-96%)	—	—	—	—	—
Net Debt (USD)	$-8.88M	$-7.40M	$-10.53M	$-23.66M	$-25.62M	$-3.50M	—
Debt / EBITDA (x)	-0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Revenue per Share (USD)	$0.05	$0.06	$0.07	$0.08	$0.14	$0.23	—
Basic EPS, GAAP (USD)	$0.24	$0.30	$0.32	$0.46	$0.35	$0.22	—
Free Cash Flow per Share (USD)	$-0.23	$-0.25	$-0.29	$-0.41	$-0.46	$-0.23	—
Book Value per Share (USD)	$0.12	$0.12	$0.27	$0.56	$0.75	$0.28	—
Tangible Book Value per Share (USD)	$0.12	$0.12	$0.27	$0.56	$0.75	$0.28	—
Basic Weighted Avg Shares (shares)	63.58M	50.88M	45.64M	37.02M	28.55M	17.13M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Working Capital (USD)	$7.78M	$5.24M	$10.31M	$23.79M	$26.30M	$5.88M	—
LT Debt (USD)	$13.00K	$161.00K	—	—	—	—	—
Total Equity (USD)	$9.05M	$6.90M	$12.16M	$25.42M	$26.96M	$5.65M	$3.29M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Sales/Revenue/Turnover (USD)	$3.38M	$3.29M	$3.23M	$3.08M	$4.14M	$3.87M	—
Depreciation Expense (USD)	$295.00K	$332.00K	$323.00K	$248.00K	$127.00K	$63.00K	—
Net Income, GAAP (USD)	$-15.06M	$-15.32M	$-14.65M	$-16.98M	$-9.89M	$-3.73M	—
Operating Cash Flow (USD)	$-14.57M	$-12.56M	$-12.55M	$-14.29M	$-12.61M	$-3.69M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 7 quarters

IceCure Medical Ltd.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ICCM with peers